ப்ரொஃபெஸர் லின் ஷென் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ரொஃபெஸர் லின் ஷென். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ரொஃபெஸர் லின் ஷென் Today - Breaking & Trending Today

Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor

Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor
News provided by
Share this article
Share this article
BEIJING, Aug. 2, 2021 /PRNewswire/ Jacobio Pharmaceuticals (1167.HK) today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 in China.
JAB-21822 is Jacobio s innovative in-house small molecule anti-cancer drug, which is designed to target the KRAS G12C mutation. It will be used to treat advanced solid tumors with KRAS G12C mutation, including but not limited to non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors. The global incidence of the KRAS G12C mutation in patients with NSCLC, ovarian cancer, CRC and pancreatic cancer reached approximately 295,000 in 2019. ....

United States , Lin Shen , Yinxiang Wang , Prnewswire Jacobio Pharmaceuticals , Professor Lin Shen , Beijing Cancer , ஒன்றுபட்டது மாநிலங்களில் , லின் ஷென் , ப்ரொஃபெஸர் லின் ஷென் , பெய்ஜிங் புற்றுநோய் ,

Transcenta Provides Program Update for Anti-Claudin18.2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer

Transcenta Provides Program Update for Anti-Claudin18.2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Lin Shen , Michael Shi , Prnewswire Transcenta Holding Limited , Clinical Development Centers , Transcenta Holding , Product Development Center , Translational Research Center , Transcenta Immune Tolerance Breaking Technology , Business Development , Holding Limited , Professor Lin Shen , Beijing Cancer , Immune Tolerance Breaking Technology , Manufacturing Facility , External Partnering Center , ஒன்றுபட்டது மாநிலங்களில் , லின் ஷென் , மைக்கேல் ஷி , மருத்துவ வளர்ச்சி மையங்கள் , ப்ராடக்ட் வளர்ச்சி மையம் , மொழிபெயர்ப்பு ஆராய்ச்சி மையம் , வணிக வளர்ச்சி , வைத்திருத்தல் வரையறுக்கப்பட்டவை , ப்ரொஃபெஸர் லின் ஷென் , பெய்ஜிங் புற்றுநோய் ,

Transcenta Announced Completion of First Patient Dosing in PET-CT Imaging Study of Radionuclide-Labeled CLDN18.2 Antibody

Share this article
Share this article
SUZHOU, China, June 1, 2021 /PRNewswire/ Transcenta Holding Limited ( Transcenta ), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced completion of first patient dosing in PET-CT imaging study of radionuclide-labeled CLDN18.2 antibody.
The study was led by Professor Lin Shen and Dr. Hua Zhu, from Beijing Cancer Hospital, the objective of the study is to construct a non-invasive approach of
124I-18B10 PET-CT to detect the CLDN18.2 expression of tumor lesions in patients with gastrointestinal and other solid tumors, and to identify patients benefited from CLDN18.2 targeting treatment. The current preclinical findings showed that the antibody probe has high specificity to CLDN18.2 and it was specifically enriched in CLDN18.2 positive tumor site in tumor-bearing mice rather than normal tissues. The results of this study were p ....

United States , Lin Shen , Michael Shi , Zhua Zhu , Prnewswire Transcenta Holding Limited , Clinical Development Centers , Transcenta Holding , Virtual Congress , Product Development Center , Translational Research Center , Business Development , Holding Limited , Professor Lin Shen , Beijing Cancer Hospital , Anticancer Therapies , Beijing Cancer , Manufacturing Facility , External Partnering Center , ஒன்றுபட்டது மாநிலங்களில் , லின் ஷென் , மைக்கேல் ஷி , ஹுவா ஜு , மருத்துவ வளர்ச்சி மையங்கள் , மெய்நிகர் காங்கிரஸ் , ப்ராடக்ட் வளர்ச்சி மையம் , மொழிபெயர்ப்பு ஆராய்ச்சி மையம் ,

Transcenta Announced the Results of the Phase I Clinical Study of PD-L1 Antibody MSB2311 with Advanced Solid Tumors and Hematological Malignancies

Share this article
Share this article
SUZHOU, China, May 19, 2021 /PRNewswire/ Transcenta Holding Limited ( Transcenta ), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced that the updated Phase I clinical study (NCT04272944) data on the safety and efficacy of MSB2311, a pH-dependent PD-L1 antibody, in Chinese patients with advanced solid tumors and hematological malignancies have been presented as an abstract online publication at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Abstract #e14547, 5:00 PM, U.S. East Time, Wednesday, May 19, 2021).
The study, presented at the 2021 ASCO annual meeting by abstract, was led by Professor Lin Shen from Beijing Cancer Hospital, and was a Phase I study of MSB2311 with a unique pH-dependent antigen binding property in Chinese patients with advanced solid tumors and lymphoma. Its primary objectiv ....

United States , Lin Shen , Michael Shi , Prnewswire Transcenta Holding Limited , Clinical Development Centers , Transcenta Holding , Product Development Center , Translational Research Center , Business Development , Holding Limited , American Society , Clinical Oncology , Professor Lin Shen , Beijing Cancer Hospital , Beijing Cancer , Two Phase , Manufacturing Facility , External Partnering Center , Transcenta Holding Limited , ஒன்றுபட்டது மாநிலங்களில் , லின் ஷென் , மைக்கேல் ஷி , மருத்துவ வளர்ச்சி மையங்கள் , ப்ராடக்ட் வளர்ச்சி மையம் , மொழிபெயர்ப்பு ஆராய்ச்சி மையம் , வணிக வளர்ச்சி ,

Transcenta Announced the Results of the Phase I Clinical Study of PD-L1 Antibody MSB2311 with Advanced Solid Tumors and Hematological Malignancies

Transcenta Announced the Results of the Phase I Clinical Study of PD-L1 Antibody MSB2311 with Advanced Solid Tumors and Hematological Malignancies
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Lin Shen , Michael Shi , Prnewswire Transcenta Holding Limited , Clinical Development Centers , Transcenta Holding , Product Development Center , Translational Research Center , Business Development , Holding Limited , American Society , Clinical Oncology , Professor Lin Shen , Beijing Cancer Hospital , Beijing Cancer , Two Phase , Manufacturing Facility , External Partnering Center , ஒன்றுபட்டது மாநிலங்களில் , லின் ஷென் , மைக்கேல் ஷி , மருத்துவ வளர்ச்சி மையங்கள் , ப்ராடக்ட் வளர்ச்சி மையம் , மொழிபெயர்ப்பு ஆராய்ச்சி மையம் , வணிக வளர்ச்சி , வைத்திருத்தல் வரையறுக்கப்பட்டவை ,